- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00534105
Lipid Metabolism in Gestational Diabetes
Study of Lipid Metabolism in Gestational Diabetes
The purpose of this pilot study is to determine if, during pregnancy, women with GDM have an exaggerated lipid response compared to non-gestational diabetics. If a difference is noted, further studies will explore the possibility of screening gestational diabetics during their pregnancy for hyperlipidemia to determine if prenatal screening can predict postpartum risk for hyperlipidemia. In addition the relationship, if any between maternal lipid dysfunction and placental disease will be explored.
This will be a prospective cohort study. As part of routine prenatal care, women receive a one hour glucose challenge test to screen for gestational diabetes. Those women with elevated values then require a three hour glucose tolerance test, which is a diagnostic test for gestational diabetes. All women that are scheduled to receive a three hour GTT will be identified and ask to enroll in this study. 46 women whose three hour GTT is normal and thus do not have GDM, will be compared to 46 women with an abnormal three hour GTT and thus would have the diagnosis of GDM. Enrolled women will have a lipid panel consisting of; total cholesterol, triglycerides, HDL and LDL cholesterol at the time of their fasting glucose blood sample. In addition, a repeat lipid panel will be sent at the time of the third hour sample, to assess changes, if any due to the glucose challenge. Umbilical cord blood samples will be sent in order to obtain newborn lipid profiles. Women in both the GDM and normal groups will be asked to return 6-8 weeks
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
The purpose of this pilot study is to determine if, during pregnancy, women with GDM have an exaggerated lipid response compared to non-gestational diabetics. If a difference is noted, further studies will explore the possibility of screening gestational diabetics during their pregnancy for hyperlipidemia to determine if prenatal screening can predict postpartum risk for hyperlipidemia. In addition the relationship, if any between maternal lipid dysfunction and placental disease will be explored. Subsequent studies could also explore the possible perinatal complications associated with elevated lipids and or metabolic syndrome.
C. Experimental Design, Methodology and Expected Results
Study Design:
We propose a prospective cohort design.
Study Population:
All women that are scheduled to receive a three hour GTT to rule out gestational diabetes would be identified and ask to enroll in this study. Specifically, eligible patients will be women who failed their glucose challenge test (GCT) and are scheduled for the follow-up three hour glucose tolerance test (GTT). The GCT is routinely performed among all prenatal care patients at 24-28 wks gestation. The 3 hour GTT requires patients to be fasting overnight. A fasting blood glucose is sampled, and the patients are given a 100 gram glucose drink. Serum glucose samples are then taken at one, two and three hours after the glucose loading. The "exposed" group will be defined as women diagnosed with GDM (elevated glucose values on two or more samples in the three hour GTT). The "unexposed" group will be defined as women with no abnormal glucose values in the three hour GTT.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Massachusetts
-
Springfield, Massachusetts, Spojené státy, 01199
- Baystate Medical Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Pregnancy
- Abnormal one hour glucose challenge test
- "Normal" controls group one hour test between 135 mg% and 150 mg%
- "Gestational diabetic" group with two abnormal values on a 3 hour GTT
Exclusion Criteria:
- History of diagnosis of diabetes, hypertension, heart disease or chronic renal disease
- Prior history of lipid disorder or metabolic syndrome
- Current medications thought to adversely influence glucose tolerance (i.e. prednisone or other steroids and systemic beta-mimetic drugs)
- Non-singleton pregnancy
- < 16 years of age or over 40 years of age
- Not planning to deliver at Baystate Medical Center
- Twins
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Kohorta
- Časové perspektivy: Budoucí
Kohorty a intervence
Skupina / kohorta |
Intervence / Léčba |
---|---|
Gestational Diabetics
Patients with Gestational Diabetes
|
|
2
Normal pregnant women without gestational diabetes
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Cholesterol
Časové okno: Postpartum
|
Cholesterol values were obtained at least 6 weeks postpartum from the gestational diabetic group and the normal controls
|
Postpartum
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Triglyceride Values
Časové okno: Postpartum
|
Triglyceride values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.
|
Postpartum
|
HDL
Časové okno: Postpartum
|
Triglyceride values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.
|
Postpartum
|
LDL
Časové okno: Postpartum
|
LDL values were obtained at least 6 weeks postpartum in both the gestational diabetic group and the normal controls.
|
Postpartum
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Glenn R Markenson, MD, Baystate Medical Center
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- IRB07-121
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Total Cholesterol
-
University of PennsylvaniaBristol-Myers SquibbDokončeno
-
Zimmer BiometDokončenoRevmatoidní artritida | Bolest kolene | Chronická osteoartróza | Avaskulární nekróza kondylu femuru | Střední varus, valgus nebo flexní deformitySpojené státy
-
Eunice Kennedy Shriver National Institute of Child...Dokončeno
-
Zimmer BiometNáborRevmatoidní artritida | Bolest kolene | Chronická osteoartróza | Avaskulární nekróza kondylu femuru | Střední varus, valgus nebo flexní deformityBelgie, Německo, Itálie, Izrael, Švýcarsko
-
Navigen, Inc.National Institute of Allergy and Infectious Diseases (NIAID); CovanceDokončeno
-
University of PennsylvaniaAstraZenecaDokončeno
-
Clinical Research Center for End Stage Renal Disease...Ministry of Health & Welfare, KoreaDokončenoHypercholesterolémieKorejská republika
-
University of PaviaAktivní, ne náborGastro ezofageální reflux | Zubní erozeItálie
-
Eunice Kennedy Shriver National Institute of Child...Dokončeno
-
Assiut UniversityNeznámýKojení, exkluzivní